PMID- 35987648
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220826
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Aug 20
TI  - The perirenal fat thickness was independently associated with serum uric acid 
      level in patients with type 2 diabetes mellitus.
PG  - 210
LID - 10.1186/s12902-022-01081-9 [doi]
LID - 210
AB  - BACKGROUND: Obesity is an important risk factor for hyperuricemia. We aimed to 
      explore the relationship between perirenal fat thickness (PrFT) and paranephric 
      fat thickness (PnFT) and serum uric acid (SUA) in patients with type 2 diabetes 
      mellitus (T2DM). METHODS: This was a cross-sectional study involving 257 patients 
      with T2DM recruited from Beijing Luhe Hospital from September 2019 to May 2020. 
      The basic and clinical information such as age, gender, duration of diabetes was 
      collected through the medical records. All patients underwent a physical 
      examination including height, weight, waist circumference, hip circumference, 
      systolic blood pressures and diastolic blood pressure. The venous blood and urine 
      samples were collected to measure SUA, fasting blood glucose, total cholesterol, 
      triglyceride, low-density lipoprotein-cholesterol, high-density 
      lipoprotein-cholesterol, serum creatinine, blood urea nitrogen and glycosylated 
      hemoglobin. PrFT and PnFT were measured via ultrasonography. Pearson correlation 
      test and linear regression analysis were used to analyze the association between 
      PrFT and PnFT and SUA. RESULTS: We found that PrFT and PnFT increased according 
      to the tertiles of SUA level (P = 0.001 and P = 0.009, respectively). In 
      addition, the PrFT and PnFT were positively associated with SUA level (r = 0.25, 
      P < 0.001, r = 0.23, P < 0.001, respectively). Moreover, this association was 
      stronger in males, non-obesity patients and patients with normal renal function. 
      In the multivariate analysis, the PrFT was independently associated with SUA 
      level after adjusting confounding factors. CONCLUSIONS: The PrFT was 
      independently associated with SUA level in patients with T2DM.
CI  - (c) 2022. The Author(s).
FAU - Yang, Yuxian
AU  - Yang Y
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
FAU - Ma, Yan
AU  - Ma Y
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
FAU - Cheng, Yanan
AU  - Cheng Y
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
FAU - Xu, Yuechao
AU  - Xu Y
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
FAU - Fang, Yuan
AU  - Fang Y
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China.
FAU - Ke, Jing
AU  - Ke J
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China. kejing@ccmu.edu.cn.
FAU - Zhao, Dong
AU  - Zhao D
AD  - Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, 
      Capital Medical University, Beijing, China. zhaodong@ccmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220820
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 268B43MJ25 (Uric Acid)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Cholesterol
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Humans
MH  - Kidney/physiology
MH  - Male
MH  - Obesity/complications
MH  - Risk Factors
MH  - *Uric Acid
PMC - PMC9392942
OTO - NOTNLM
OT  - Obesity
OT  - Paranephric fat thickness
OT  - Perirenal fat thickness
OT  - Serum uric acid
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/21 06:00
MHDA- 2022/08/24 06:00
PMCR- 2022/08/20
CRDT- 2022/08/20 23:34
PHST- 2022/01/08 00:00 [received]
PHST- 2022/06/21 00:00 [accepted]
PHST- 2022/08/20 23:34 [entrez]
PHST- 2022/08/21 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/08/20 00:00 [pmc-release]
AID - 10.1186/s12902-022-01081-9 [pii]
AID - 1081 [pii]
AID - 10.1186/s12902-022-01081-9 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2022 Aug 20;22(1):210. doi: 10.1186/s12902-022-01081-9.